NEW YORK, Sept. 2, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Atherosclerosis Global Clinical Trials Review, H2, 2014
http://www.reportlinker.com/p02353408/Atherosclerosis-Global-Clinical-Trials-Review-H2-2014.html
Atherosclerosis Global Clinical Trials Review, H2, 2014
Summary
GlobalData's clinical trial report, "Atherosclerosis Global Clinical Trials Review, H2, 2014" provides data on the Atherosclerosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Atherosclerosis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Atherosclerosis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)
Reasons to buy
- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
Introduction 6Atherosclerosis 6Report Guidance 6Clinical Trials by Region 7Clinical Trials and Average Enrollment by Country 8Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10Top Five Countries Contributing to Clinical Trials in Europe 11Top Countries Contributing to Clinical Trials in North America 12Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13Top Five Countries Contributing to Clinical Trials in Central and South America 14Clinical Trials by G7 Countries: Proportion of Atherosclerosis to Cardiovascular Clinical Trials 15Clinical Trials by Phase in G7 Countries 16Clinical Trials in G7 Countries by Trial Status 17Clinical Trials by E7 Countries: Proportion of Atherosclerosis to Cardiovascular Clinical Trials 18Clinical Trials by Phase in E7 Countries 19Clinical Trials in E7 Countries by Trial Status 20Clinical Trials by Phase 21In Progress Trials by Phase 22Clinical Trials by Trial Status 23Clinical Trials by End Point Status 24Unaccomplished Trials of Atherosclerosis 25Subjects Recruited Over a Period of Time 31Clinical Trials by Sponsor Type 32Prominent Sponsors 33Top Companies Participating in Atherosclerosis Therapeutics Clinical Trials 34Prominent Drugs 36Latest Clinical Trials News on Atherosclerosis 37Jul 30, 2014: AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 37Clinical Trial Profiles 38Clinical Trial Overview of Top Companies 38Merck & Co., Inc. 38Clinical Trial Overview of Merck & Co., Inc. 38GlaxoSmithKline plc 41Clinical Trial Overview of GlaxoSmithKline plc 41AstraZeneca PLC 43Clinical Trial Overview of AstraZeneca PLC 43Pfizer Inc. 45Clinical Trial Overview of Pfizer Inc. 45F. Hoffmann-La Roche Ltd. 47Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 47Novartis AG 48Clinical Trial Overview of Novartis AG 48Bristol-Myers Squibb Company 49Clinical Trial Overview of Bristol-Myers Squibb Company 49Eli Lilly and Company 50Clinical Trial Overview of Eli Lilly and Company 50Daiichi Sankyo Company, Limited 51Clinical Trial Overview of Daiichi Sankyo Company, Limited 51Sanofi 52Clinical Trial Overview of Sanofi 52Clinical Trial Overview of Top Institutes / Government 53National Heart, Lung, and Blood Institute 53Clinical Trial Overview of National Heart, Lung, and Blood Institute 53Korea University 58Clinical Trial Overview of Korea University 58Brigham and Women's Hospital 59Clinical Trial Overview of Brigham and Women's Hospital 59Mayo Clinic 60Clinical Trial Overview of Mayo Clinic 60National Institute on Aging 61Clinical Trial Overview of National Institute on Aging 61Tehran University of Medical Sciences 62Clinical Trial Overview of Tehran University of Medical Sciences 62National Defense Medical College 63Clinical Trial Overview of National Defense Medical College 63University of California, San Francisco 64Clinical Trial Overview of University of California, San Francisco 64Johns Hopkins University 65Clinical Trial Overview of Johns Hopkins University 65National Taiwan University Hospital 66Clinical Trial Overview of National Taiwan University Hospital 66Five Key Clinical Profiles 67Appendix 124Abbreviations 124Definitions 124Research Methodology 125Secondary Research 126About GlobalData 126Contact Us 126Disclaimer 127Source 127
List of Tables
Atherosclerosis Therapeutics, Global, Clinical Trials by Region, 2014* 7Atherosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9Atherosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10Atherosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11Atherosclerosis Therapeutics Clinical Trials, North America, Top Countries, 2014* 12Atherosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2014* 13Atherosclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14Proportion of Atherosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17Proportion of Atherosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20Atherosclerosis Therapeutics, Global, Clinical Trials by Phase, 2014* 21Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22Atherosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23Atherosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24Atherosclerosis Therapeutics, Global, Suspended Clinical Trials, 2014* 25Atherosclerosis Therapeutics, Global, Withdrawn Clinical Trials, 2014* 26Atherosclerosis Therapeutics, Global, Terminated Clinical Trials, 2014* 27Atherosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31Atherosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 32Atherosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33Atherosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 35Atherosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014* 38Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014* 41Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by AstraZeneca PLC, 2014* 43Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 45Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 47Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 48Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014* 49Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Eli Lilly and Company, 2014* 50Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2014* 51Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 52Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Heart, Lung, and Blood Institute, 2014* 53Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Korea University, 2014* 58Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Brigham and Women's Hospital, 2014* 59Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 60Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute on Aging, 2014* 61Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Tehran University of Medical Sciences, 2014* 62Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Defense Medical College, 2014* 63Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 64Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by Johns Hopkins University, 2014* 65Atherosclerosis Therapeutics Clinical Trials Market, Global, Clinical Trials by National Taiwan University Hospital, 2014* 66
List of Figures
Atherosclerosis Therapeutics, Global, Clinical Trials by Region (%), 2014* 7Atherosclerosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9Atherosclerosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10Atherosclerosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11Atherosclerosis Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12Atherosclerosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2014* 13Atherosclerosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14Proportion of Atherosclerosis to Cardiovascular Clinical Trials, G7 Countries (%), 2014* 15Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16Atherosclerosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17Proportion of Atherosclerosis to Cardiovascular Clinical Trials, E7 Countries (%), 2014* 18Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19Atherosclerosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20Atherosclerosis Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21Atherosclerosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22Atherosclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23Atherosclerosis Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24Atherosclerosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 31Atherosclerosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 32Atherosclerosis Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 33Atherosclerosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 34Atherosclerosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 36GlobalData Methodology 125
To order this report: Atherosclerosis Global Clinical Trials Review, H2, 2014 http://www.reportlinker.com/p02353408/Atherosclerosis-Global-Clinical-Trials-Review-H2-2014.html
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article